ClinicalTrials.gg
RecruitingNCT07454135MAP HCMUpdated Sep 11, 2026

Mechanisms of Atrial Pathoelectrophysiology in HCM

An observational study in Hypertrophic Cardiomyopathy (HCM) and Atrial Fibrillation (AF), sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.

Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.

The information from this study may help improve future treatments for people who have both HCM and AF.

02

Conditions studied

  • Hypertrophic Cardiomyopathy (HCM)
  • Atrial Fibrillation (AF)

Keywords

  • hypertrophic cardiomyopathy
  • atrial fibrillation
03

In context

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

This study's planned enrollment of 40 is below the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Paroxysmal or persistent atrial fibrillation
  • Diagnosis of hypertrophic cardiomyopathy
  • Patient planning to proceed to atrial fibrillation ablation following clinical consultation
  • Age 18-80 years
  • Able and willing to provide written
  • Able and willing to comply with study follow up requirements

Exclusion criteria

Exclusion Criteria:

  • Any clinical to ablation
  • Any disease limiting to \<1 year
  • Potential participant currently pregnant or breast feeding
  • Contraindication to MRI including renal dysfunction (\<30ml/min)
  • Unable to understand verbal or written explanations given in English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with HCM and AF
06

What researchers measure

Primary outcomes

  1. Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts

    Time frame: At the time of the clinical ablation procedure

Secondary outcomes

  1. Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .

    Time frame: At the time of clinical ablation procedure

  2. Reduction in AF inducibility in silico models following simulated ablation

    Time frame: Based on measurements taken during the clinical ablation procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454135
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
May 26, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion